GNOMX Corp.
GNOMX Corp. is a biotechnology company founded in October 2022, specializing in a next-generation epigenetic and AI diagnostic platform for infectious diseases and related conditions. Their platform is based on research funded by a $46 million DARPA ECHO program contract. GNOMX aims to transform infectious disease assessment, diagnosis, and treatment by developing patent-pending epigenetic tests that can rapidly diagnose, determine exposure time, and monitor long-term effects of infections, even after the pathogen is gone. Their key products in development are ReAdmitPredict, for predicting sepsis patient hospital readmission, and LymeScreen Dx, for early detection of acute Lyme disease. They have demonstrated over 90% accuracy in a proof-of-concept study for Lyme disease detection. The company was awarded a BARDA contract to develop an assay for predicting sepsis patient readmission risk.
GNOMX Corp.
GNOMX Corp. is a biotechnology company founded in October 2022, specializing in a next-generation epigenetic and AI diagnostic platform for infectious diseases and related conditions. Their platform is based on research funded by a $46 million DARPA ECHO program contract. GNOMX aims to transform infectious disease assessment, diagnosis, and treatment by developing patent-pending epigenetic tests that can rapidly diagnose, determine exposure time, and monitor long-term effects of infections, even after the pathogen is gone. Their key products in development are ReAdmitPredict, for predicting sepsis patient hospital readmission, and LymeScreen Dx, for early detection of acute Lyme disease. They have demonstrated over 90% accuracy in a proof-of-concept study for Lyme disease detection. The company was awarded a BARDA contract to develop an assay for predicting sepsis patient readmission risk.